IACS Leadership
Head of Drug Discovery
Philip Jones, Ph.D.
Philip Jones, Ph.D., has more than a decade of drug discovery research experience from Merck Research Laboratories at three locations worldwide. During his career, Jones has led several of Merck’s oncology drug discovery programs, overseeing cross-functional project teams that have successfully delivered novel candidates into ongoing clinical trials. These include Merck’s PARP inhibitor, smoothened antagonist and histone deacetylase (HDAC) programs, as well as several undisclosed targets. Jones also was involved in the successful development of Raltegravir, the first-in-class HIV integrase inhibitor. He has extensive drug discovery experience across a broad range of target families and has coordinated research across the entire preclinical spectrum from target identification to lead optimization.
Jones received his Ph.D. in organic chemistry from the University of Nottingham, United Kingdom, and completed his post-doctoral research in the laboratory of Professor P. Knochel at Philipps-Universität Marburg, Germany.
Institute Leadership
- Giulio Draetta, M.D., Ph.D. - Director
- Lynda Chin, M.D. - Scientific Director
- Carlo Toniatti, M.D., Ph.D. - Head of Research
- Philip Jones, Ph.D. - Head of Drug Discovery
- Eric Devroe, Ph.D. - Executive Director, Strategic Alliances
- Jannik Andersen, Ph.D. - Senior Associate Director, Drug Discovery Biology
- Joseph Marszalek, Ph.D. - Senior Associate Director, Target Validation
- Timothy Heffernan, Ph.D. - Associate Director, Target Discovery
- James Horner, B.S. - Associate Director, Mouse Cancer Models
- Ming-Kuei Jang, Ph.D., - Associate Director, Neurobiology
- Alexei Protopopov, Ph.D. - Associate Director, Oncogenomics
- Jianhua (John) Zhang, Ph.D. - Associate Director, Bioinformatics